Patents by Inventor Tomoyuki Tahara
Tomoyuki Tahara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10930929Abstract: The present invention provides a Li-ion secondary cell negative-electrode material with which it is possible to adequately suppress reductive decomposition of a liquid electrolyte by an active material during charging, the Li-ion secondary cell negative-electrode material exhibiting a high discharge capacity that exceeds the theoretical capacity of graphite and exceptional initial charging efficiency and cycle characteristics. In this negative-electrode material for a Li-ion secondary cell, the surfaces of particles of SiOx (O?x<2) contain Li and at least one metallic element M selected from among Si, Al, Ti, and Zr, and have a coating of a Li-containing oxide comprising a composition in which M/Li>5 with respect to the molar ratio.Type: GrantFiled: January 6, 2017Date of Patent: February 23, 2021Assignee: JFE CHEMICAL CORPORATIONInventor: Tomoyuki Tahara
-
Publication number: 20190081323Abstract: The present invention provides a Li-ion secondary cell negative-electrode material with which it is possible to adequately suppress reductive decomposition of a liquid electrolyte by an active material during charging, the Li-ion secondary cell negative-electrode material exhibiting a high discharge capacity that exceeds the theoretical capacity of graphite and exceptional initial charging efficiency and cycle characteristics. In this negative-electrode material for a Li-ion secondary cell, the surfaces of particles of SiOx (0?x<2) contain Li and at least one metallic element M selected from among Si, Al, Ti, and Zr, and have a coating of a Li-containing oxide comprising a composition in which M/Li>5 with respect to the molar ratio.Type: ApplicationFiled: January 6, 2017Publication date: March 14, 2019Applicant: JFE Chemical CorporationInventor: Tomoyuki Tahara
-
Patent number: 9688770Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.Type: GrantFiled: May 4, 2015Date of Patent: June 27, 2017Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Tomoyuki Tahara, Yoshikatsu Kanai, Hitoshi Endou, Shiro Kataoka, Kazumasa Hasegawa, Tetsuya Yoshino
-
Patent number: 9447172Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof.Type: GrantFiled: December 27, 2013Date of Patent: September 20, 2016Assignees: KYOWA HAKKO KIRIN CO., LTD., LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGYInventors: Shinichiro Kato, Steve Granger, Shane Crotty, Sandra Rickert, Lilia Koriazova, Tomoyuki Tahara
-
Publication number: 20150307621Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.Type: ApplicationFiled: May 4, 2015Publication date: October 29, 2015Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Tomoyuki TAHARA, Yoshikatsu KANAI, Hitoshi ENDOU, Shiro KATAOKA, Kazumasa HASEGAWA, Tetsuya YOSHINO
-
Patent number: 9051374Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.Type: GrantFiled: July 12, 2013Date of Patent: June 9, 2015Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Tomoyuki Tahara, Yoshikatsu Kanai, Hitoshi Endou, Shiro Kataoka, Kazumasa Hasegawa, Tetsuya Yoshino
-
Publication number: 20140212409Abstract: The present invention relates to a method for increasing deposition of complement C3b on the bacterial surface and phagocytosis by phagocytes, a therapeutic method and a therapeutic agent for bacterial infections, using an antibody binding to a molecule on the bacterial surface, in which the antibody is modified by substituting at least one amino acid residue with other amino acid so as to show more enhanced complement-dependent cytotoxicity (CDC) than the antibody before substitution of the amino acid residue.Type: ApplicationFiled: August 13, 2013Publication date: July 31, 2014Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Sascha KRISTIAN, Mami KOYAMA, Yutaka KANDA, Tomoyuki TAHARA
-
Publication number: 20140186370Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof.Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Applicants: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, KYOWA HAKKO KIRIN CO., LTD.Inventors: SHINICHIRO KATO, STEVE GRANGER, SHANE CROTTY, SANDRA RICKERT, LILIA KORIAZOVA, TOMOYUKI TAHARA
-
Publication number: 20140127111Abstract: A method for producing lithium iron phosphate includes an aqueous solution preparation step of preparing an aqueous solution containing a phosphoric acid and a hydroxycarboxylic acid; a first preparation step of adding iron particles containing 0.1 to 2 mass % oxygen to the aqueous solution, and reacting the phosphoric acid and the hydroxycarboxylic acid in the aqueous solution with the iron particles in an oxidizing atmosphere to prepare a first reaction liquid; a second preparation step of adding a lithium source to the first reaction liquid to prepare a second reaction liquid; a third preparation step of adding a carbon source to the second reaction liquid to prepare a third reaction liquid; a precursor formation step of drying the third reaction liquid to form a lithium iron phosphate precursor; and a calcination step of calcining the lithium iron phosphate precursor in a non-oxidizing atmosphere to produce lithium iron phosphate.Type: ApplicationFiled: February 27, 2012Publication date: May 8, 2014Applicant: JFE CHEMICAL CORPORATIONInventor: Tomoyuki Tahara
-
Publication number: 20140037636Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.Type: ApplicationFiled: July 12, 2013Publication date: February 6, 2014Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Tomoyuki TAHARA, Yoshikatsu KANAI, Hitoshi ENDOU, Shiro KATAOKA, Kazumasa HASEGAWA, Tetsuya YOSHINO
-
Patent number: 8623370Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to pox virus H3L envelope protein, and combinations thereof.Type: GrantFiled: October 6, 2008Date of Patent: January 7, 2014Assignees: Kyowa Hakko Kirin Co., Ltd., La Jolla Institute for Allergy and ImmunologyInventors: Shinichiro Kato, Steve Granger, Shane Crotty, Sandra Rickert, Lilia Koriazova, Tomoyuki Tahara
-
Patent number: 8486402Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.Type: GrantFiled: May 12, 2011Date of Patent: July 16, 2013Assignee: Kyowa Hakko Kirin Co., LtdInventors: Tomoyuki Tahara, Yoshikatsu Kanai, Hitoshi Endou, Shiro Kataoka, Kazumasa Hasegawa, Tetsuya Yoshino
-
Patent number: 8420784Abstract: The invention relates to IL-1O Receptor alpha (IL-1OR?) antibodies and subsequences thereof, human and humanized IL-10 Receptor alpha (IL-IOR?) antibodies and subsequences thereof, isolated and purified IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, compositions including IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, and methods that employ IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof. The invention includes among other things, methods of treating a pathogen infection, pathogen reactivation, and methods of vaccinating or immunizing against a pathogen infection, which include, for example, administering an IL-10 Receptor alpha (IL-1OR?) antibody or subsequence, to treat a pathogen infection, pathogen reactivation or for vaccination or immunization.Type: GrantFiled: May 27, 2009Date of Patent: April 16, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Shinichiro Kato, Rachel Soloff Nugent, Tomoyuki Tahara, Paul Rogers, Aihua Song
-
Publication number: 20120292560Abstract: A method of producing lithium iron phosphate includes adding iron particles containing 0.5 mass % or more of oxygen to an aqueous solution containing a phosphoric acid, a carboxylic acid and a lithium source, and causing components contained in the aqueous solution and the iron particles to react with each other under an oxidizing atmosphere and thereby form a reaction liquid; drying the reaction liquid to form a lithium iron phosphate precursor; and baking the lithium iron phosphate precursor under a non-oxidizing atmosphere to obtain the lithium iron phosphate.Type: ApplicationFiled: December 24, 2010Publication date: November 22, 2012Applicant: JFE CHEMICAL CORPORATIONInventors: Tomoyuki Tahara, Minoru Sakai
-
Publication number: 20120032119Abstract: A method for producing lithium iron phosphate includes: an aqueous solution preparing step of preparing an aqueous solution containing a phosphoric acid and a carboxylic acid; a first forming step of adding iron particles containing 0.5 mass % or more of oxygen to the aqueous solution, and making the phosphoric acid and the carboxylic acid and the iron particles react with each other in the aqueous solution under an oxidizing atmosphere, to form a first reaction liquid is formed by; the second forming step of adding a lithium source to the first reaction liquid obtained in the synthesizing step to form a second reaction liquid; the precursor forming step of drying the second reaction liquid to form a lithium iron phosphate precursor; and the primary baking step of baking the lithium iron phosphate precursor under a non-oxidizing atmosphere thus obtaining lithium iron phosphate.Type: ApplicationFiled: March 10, 2010Publication date: February 9, 2012Applicant: JFE CHEMICAL CORPORATIONInventors: Tomoyuki Tahara, Minoru Sakai
-
Publication number: 20110280884Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.Type: ApplicationFiled: May 12, 2011Publication date: November 17, 2011Inventors: Tomoyuki TAHARA, Yoshikatsu Kanai, Hitoshi Endou, Shiro Kataoka, Kazumasa Hasegawa, Tetsuya Yoshino
-
Publication number: 20110144312Abstract: The invention relates to IL-1O Receptor alpha (IL-1OR?) antibodies and subsequences thereof, human and humanized IL-10 Receptor alpha (IL-IOR?) antibodies and subsequences thereof, isolated and purified IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, compositions including IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, and methods that employ IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof. The invention includes among other things, methods of treating a pathogen infection, pathogen reactivation, and methods of vaccinating or immunizing against a pathogen infection, which include, for example, administering an IL-10 Receptor alpha (IL-1OR?) antibody or subsequence, to treat a pathogen infection, pathogen reactivation or for vaccination or immunization.Type: ApplicationFiled: May 27, 2009Publication date: June 16, 2011Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Shinichiro Kato, Rachel Soloff Nugent, Tomoyuki Tahara, Paul Rogers, Aihua Song
-
Patent number: 7943745Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.Type: GrantFiled: April 5, 2007Date of Patent: May 17, 2011Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Tomoyuki Tahara, Yoshikatsu Kanai, Hitoshi Endou, Shiro Kataoka, Kazumasa Hasegawa, Tetsuya Yoshino
-
Publication number: 20100143367Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.Type: ApplicationFiled: April 5, 2007Publication date: June 10, 2010Inventors: Tomoyuki Tahara, Yoshikatsu Kanai, Hitoshi Endou, Shiro Kataoka, Kazumasa Hasegawa, Tetsuya Yoshino
-
Patent number: 7592005Abstract: A monoclonal antibody or a functional fragment thereof that binds to a human BST2 antigen existing on the cell surface and can be localized through internalization into the cell, a complex comprising the monoclonal antibody or a functional fragment thereof and a therapeutic agent, and a pharmaceutical composition comprising, as an active ingredient, the complex.Type: GrantFiled: December 26, 2001Date of Patent: September 22, 2009Assignee: Kirin Beer Kabushiki KaishaInventor: Tomoyuki Tahara